"As Dr. Sathananthan has stated, these results do not come as a surprise. Extensive preclinical
work in partnership with a large number of leading physicians has demonstrated a superior
hemodynamic result compared to commercially available products, both in native aortic stenosis
and in valve-in-valve procedures. With a rapidly growing number of degenerating AVRs, this
valve will have a dominant role in treating these patients. “"
$3b market just for ViV!!!
Ann: Exceptional Results in Second Valve-in-Valve Case, page-2
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.23 |
Change
-0.580(2.93%) |
Mkt cap ! $369.6M | |||
| Open | High | Low | Value | Volume |
| $19.99 | $19.99 | $19.23 | $438.0K | 22.52K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50 | $19.23 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.50 | 100 | 1 |
View Market Depth
| Last trade - 16.10pm 22/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.26 |
Change
-0.580 ( 4.18 %) |
||||
| Open | High | Low | Volume | ||
| $19.59 | $19.75 | $19.26 | 294 | ||
| Last updated 15.59pm 22/05/2024 ? | |||||
| AVR (ASX) Chart |